Literature DB >> 11229520

Analytical evaluation of primer engineered multiplex polymerase chain reaction-restriction fragment length polymorphism for detection of factor V Leiden and prothrombin G20210A.

S Huber1, K J McMaster, K V Voelkerding.   

Abstract

Factor V Leiden and prothrombin G20210A are clinically relevant genetic risk factors for venous thrombosis. Analysis for both mutations is increasingly being performed on patients exhibiting hypercoagulability. The goal of the current study was to evaluate the performance of primer-engineered multiplex polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) for the simultaneous detection of factor V Leiden and prothrombin G20210A. Primer-engineered multiplex PCR-RFLP methods for the detection of factor V Leiden and prothrombin G20210A from the medical literature were reviewed. A modified method was optimized in which both mutations generate HindIII RFLPs and the prothrombin amplicon contains an invariant HindIII recognition site to assess the completeness of endonuclease digestion. Digested amplification products were analyzed by agarose gel electrophoresis in a single gel lane and visualized by ethidium bromide. Primer-engineered multiplex PCR-RFLP was used to analyze 205 human genomic DNA samples whose factor V Leiden genotypes had been previously determined by MnlI PCR-RFLP. Complete concordance for factor V Leiden genotypes was observed between the two methods in the 205-sample cohort comprising 139 wild-type, 62 heterozygous mutant, and four homozygous mutant individuals. For prothrombin G20210A, primer-engineered multiplex PCR-RFLP identified 196 wild-type and nine heterozygous mutant individuals in the 205-sample cohort. To independently verify prothrombin genotypes, the nine heterozygous mutants and an additional 11 wild-type patient samples (representing 10% of patient samples) were subjected to DNA sequencing. Complete concordance was observed between DNA sequencing and primer-engineered multiplex PCR-RFLP results. In further validation, 123 of the DNA samples consisting of four heterozygous mutant and 119 wild type individuals were genotyped with the Invader Assay for Factor II (prothrombin G20210A). Results showed 100% concordance between the Invader Assay and primer-engineered multiplex PCR-RFLP. A primer-engineered multiplex PCR-RFLP based on single restriction endonuclease digestion has been evaluated and shown to simultaneously and accurately detect factor V Leiden and prothrombin G20210A mutations. The method is robust and readily adaptable to the clinical molecular diagnostic laboratory.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11229520      PMCID: PMC1906911          DOI: 10.1016/S1525-1578(10)60631-9

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  24 in total

Review 1.  Clinical, genetic, and pharmacogenetic applications of the Invader assay.

Authors:  R W Kwiatkowski; V Lyamichev; M de Arruda; B Neri
Journal:  Mol Diagn       Date:  1999-12

2.  Two multiplex PCR-based DNA assays for the thrombosis risk factors prothrombin G20210A and coagulation factor V G1691A polymorphisms.

Authors:  X Xu; K A Bauer; J H Griffin
Journal:  Thromb Res       Date:  1999-03-15       Impact factor: 3.944

3.  An even easier method for one-step detection of both FV Leiden and FII G20210A transition.

Authors:  G Muriel; B Christine; J Philippe; M Christophe; S J Francois; A M Patricia
Journal:  Blood       Date:  1998-11-01       Impact factor: 22.113

4.  Rapid detection of the prothrombin 20210 A variation by allele specific PCR.

Authors:  S R Poort; R M Bertina; H L Vos
Journal:  Thromb Haemost       Date:  1997-09       Impact factor: 5.249

Review 5.  Factor V Leiden and other coagulation factor mutations affecting thrombotic risk.

Authors:  R M Bertina
Journal:  Clin Chem       Date:  1997-09       Impact factor: 8.327

6.  Polymorphism identification and quantitative detection of genomic DNA by invasive cleavage of oligonucleotide probes.

Authors:  V Lyamichev; A L Mast; J G Hall; J R Prudent; M W Kaiser; T Takova; R W Kwiatkowski; T J Sander; M de Arruda; D A Arco; B P Neri; M A Brow
Journal:  Nat Biotechnol       Date:  1999-03       Impact factor: 54.908

7.  A rapid screening method for the factor V Arg506-->Gln mutation.

Authors:  S Gandrille; M Alhenc-Gelas; M Aiach
Journal:  Blood Coagul Fibrinolysis       Date:  1995-05       Impact factor: 1.276

8.  Detection and Identification of Base Alterations Within the Region of Factor V Leiden by Fluorescent Melting Curves.

Authors: 
Journal:  Mol Diagn       Date:  1998-12

9.  Mutation in blood coagulation factor V associated with resistance to activated protein C.

Authors:  R M Bertina; B P Koeleman; T Koster; F R Rosendaal; R J Dirven; H de Ronde; P A van der Velden; P H Reitsma
Journal:  Nature       Date:  1994-05-05       Impact factor: 49.962

10.  Simultaneous polymerase chain reaction restriction fragment length polymorphism identification of the factor V Leiden allele and the prothrombin 20210A mutation.

Authors:  J D Wisotzkey; T Bell; J S Monk
Journal:  Diagn Mol Pathol       Date:  1998-06
View more
  8 in total

1.  Screening Donors for Rare Antigen Constellations.

Authors:  Franz F Wagner
Journal:  Transfus Med Hemother       Date:  2009-05-26       Impact factor: 3.747

2.  Risk of cerebral venous thrombosis and novel gene polymorphisms of the coagulation and fibrinolytic systems.

Authors:  Christoph Lichy; Tuan Dong-Si; Karl Reuner; Just Genius; Henning Rickmann; Toni Hampe; Tarah Dolan; Felix Stoll; Armin Grau
Journal:  J Neurol       Date:  2005-09-16       Impact factor: 4.849

3.  G2691A and C2491T mutations of factor V gene and pre-disposition to myocardial infarction in Morocco.

Authors:  Wiam Hmimech; Brehima Diakite; Hind Hassani Idrissi; Khalil Hamzi; Farah Korchi; Dalila Baghdadi; Rachida Habbal; Sellama Nadifi
Journal:  Biomed Rep       Date:  2016-09-30

4.  Increased Factor V Leiden frequency is associated with venous thrombotic events among young Brazilian patients.

Authors:  Adriano de Paula Sabino; Daniela Amorim Melgaço Guimarães; Daniel Dias Ribeiro; Sabrina Guimarães Paiva; Luci Maria Sant'Ana Dusse; Maria das Graças Carvalho; Ana Paula Fernandes
Journal:  J Thromb Thrombolysis       Date:  2007-03-31       Impact factor: 2.300

5.  Assessment of hypercoagulability markers and lipid levels in postmenopausal women undergoing either oral or transdermal hormone replacement therapy.

Authors:  Daniela Amorim Melgaço Guimarães; Maria das Graças Carvalho; Jarbas Cardoso; Marinez de Oliveira Sousa; Romerson Martins Franco; Hilton de Almeida Franco; Túlio César Alvim; George da Silva Teixeira; Luci Maria SantAna Dusse; Ana Paula Fernandes
Journal:  J Thromb Thrombolysis       Date:  2007-12-04       Impact factor: 2.300

6.  Risk of colorectal cancer and clotting factor gene polymorphisms in Moroccan Population.

Authors:  Imane Baghad; Driss Erguibi; Farid Chehab; Sellama Nadifi
Journal:  Int J Adv Res (Indore)       Date:  2017

7.  Risk factors for deep vein thrombosis of lower extremities in Sudanese women.

Authors:  Nadir Ahmed Ibrahim; Fathelrahman M Hassan; Mahmoud Mohamed Elgari; Sana Eltahir Abdalla
Journal:  Vasc Health Risk Manag       Date:  2018-08-20

8.  Variants of Genes Involved in Metabolism of Folate Among Patients with Breast Cancer: Association of TYMS 3R Allele with Susceptibility to Breast Cancer and Metastasis.

Authors:  Zohreh Rahimi; Maryam Bozorgi Zarini; Ziba Rahimi; Ebrahim Shakiba; Asad Vaisi-Raygani; Mohammad Taher Moradi; Kheirolah Yari
Journal:  Iran J Pathol       Date:  2020-11-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.